8-K: ALX Oncology Q1 2026 Results: Promising Data, Leadership Boost

ALX Oncology reported Q1 2026 financial results, highlighting encouraging clinical data for evorpacept in HER2-positive breast cancer and strengthening its leadership team.

Summary

• ALX Oncology announced its first quarter 2026 financial results, reporting a GAAP net loss of $17.9 million, or $0.17 per share, an improvement from the $30.8 million net loss in Q1 2025.
• The company presented promising data from a Phase 1b/2 trial of evorpacept combined with zanidatamab in HER2-positive metastatic breast cancer patients, showing durable responses, particularly in those with high CD47 expression.
• All patients (5/5) with HER2-positive disease and high CD47 expression achieved responses, with a median duration of response of 20.2 months and median progression-free survival of 22.1 months.
• The Phase 2 ASPEN-09-Breast trial evaluating evorpacept in HER2-positive breast cancer is on track for topline data mid-2027.
• The Phase 1 trial for ALX2004, an EGFR-targeted ADC, is enrolling well, with safety data expected in the second half of 2026.
• ALX Oncology strengthened its leadership with the appointment of Jeff Knight as Chief Development and Operating Officer.
• The company ended Q1 2026 with $169.1 million in cash, cash equivalents, and investments, which it believes is sufficient to fund operations through the first half of 2028.
• Research and Development expenses decreased to $13.6 million in Q1 2026 from $23.9 million in Q1 2025, attributed to workforce reductions and pipeline prioritization.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive filing due to encouraging clinical data in a key indication, a strengthened balance sheet, and strategic leadership additions, despite the ongoing net loss.

Positives

• All patients (5/5) with HER2-positive disease and high CD47 expression in the Phase 1b/2 trial showed durable responses to evorpacept + zanidatamab, with a median duration of response of 20.2 months.
• Patients with HER2-positive disease in the Phase 1b/2 trial demonstrated a 60% confirmed objective response rate (cORR) and a median progression-free survival (mPFS) of 8.3 months.
• The company raised $150 million in gross proceeds from a registered equity offering in February 2026, strengthening its balance sheet.
• Cash, cash equivalents, and investments stood at $169.1 million as of March 31, 2026, providing an estimated runway through the first half of 2028.
• GAAP net loss significantly decreased to $17.9 million in Q1 2026 from $30.8 million in Q1 2025.
• Research and Development expenses decreased by $10.3 million year-over-year due to workforce reductions and pipeline prioritization.
• Jeff Knight was appointed as Chief Development and Operating Officer, bringing over 30 years of biopharmaceutical experience.
• The Phase 1 trial for ALX2004 is enrolling well, on track for safety data in 2H 2026.

Negatives

• The overall confirmed objective response rate (cORR) among all 24 patients in the Phase 1b/2 trial was 33%, with a median progression free survival (mPFS) of 3.6 months.
• Patients with HER2-positive disease and low CD47 expression in the Phase 1b/2 trial had a cORR of 25% and mPFS of 3.4 months.
• The company reported a GAAP net loss of $17.9 million for the quarter.
• Weighted-average shares outstanding increased significantly to 104,573,657 in Q1 2026 from 53,359,338 in Q1 2025, potentially diluting existing shareholders.

Risks

• Forward-looking statements involve substantial risks and uncertainties, including risks related to future results of operations, business strategy, product candidates, clinical trial results, regulatory approvals, and timing and likelihood of success.
• The company's success depends on the successful development and commercialization of its product candidates, evorpacept and ALX2004, which are still in clinical development.
• The effectiveness of evorpacept as a cornerstone therapy is still being established through ongoing clinical trials.
• The company faces competition from other biotechnology and pharmaceutical companies developing cancer therapies.

Future Outlook

The company expects to provide topline data for 80 patients in the Phase 2 ASPEN-09-Breast trial in mid-2027 and safety data from the dose-escalation phase of the Phase 1 ALX2004 trial in the second half of 2026. Management believes current cash, cash equivalents, and investments are sufficient to fund planned operations through the first half of 2028.

Management Comments

• "We are encouraged by the data presented yesterday at the ESMO Breast Cancer 2026 congress, which reinforce the potential of our CD47-inhibitor evorpacept to provide durable responses in patients with HER2-positive cancers that express high levels of CD47," said Jason Lettmann, Chief Executive Officer at ALX Oncology.
• "Coupled with the previous results from the ASPEN-06 gastric cancer trial, these findings validate our development strategy and reinforce our confidence in the ongoing Phase 2 ASPEN-09-Breast trial."
• "Additionally, we are pleased with the progress of the Phase 1 trial for ALX2004, which remains on track to report dose-escalation safety data this year."
• "With a strengthened balance sheet, we are well-positioned to deliver key data readouts from both ongoing clinical programs."
• "It is encouraging to see clinical improvements in patients with heavily pre-treated HER2-positive breast cancer. As the landscape for HER2-positive advanced breast cancer continues to evolve, there remains a clear need for new options once patients disease progresses following treatment with currently available therapies, including trastuzumab deruxtecan," said Sara Hurvitz, M.D., Professor, Senior Vice President and Director, Clinical Research Division and Smith Family Endowed Chair in Womens Health at Fred Hutchinson Cancer Center, University of Washington.
• "The findings from this Phase 1b/2 trial suggest that combining evorpacept with HER2-targeted agents, guided by CD47 biomarker-driven selection, may offer a promising strategy to address this unmet need."

Industry Context

StockSavvy.ai notes that ALX Oncology's focus on CD47 inhibition in HER2-positive cancers aligns with a broader industry trend of developing targeted therapies and utilizing biomarkers to identify patient populations most likely to benefit from specific treatments, particularly in areas with high unmet need like refractory breast cancer.

Comparison to Industry Standards

• The reported cORR of 60% and mPFS of 8.3 months in HER2-positive patients with high CD47 expression in the Phase 1b/2 trial is a notable outcome, especially considering these patients had previously received ENHERTU.
• The median duration of response of 20.2 months for this subgroup is particularly encouraging and suggests potential for long-term benefit, a key benchmark in oncology drug development.
• While the overall cORR of 33% is less striking, the clear differentiation based on CD47 expression supports the biomarker-driven strategy, a common approach in modern oncology drug development to improve efficacy and patient selection.
• The decrease in R&D expenses by approximately 43% year-over-year, while potentially concerning for growth, reflects a strategic prioritization of pipeline assets, a common practice for clinical-stage biotech companies managing resources.

Management Changes

Stakeholder Impact

• Shareholders: Potential dilution from the February 2026 equity offering, but also potential upside from positive clinical trial results and improved financial stability.
• Employees: The appointment of a new Chief Development and Operating Officer may signal a renewed focus on operational execution and program advancement.
• Creditors: The company's cash position and projected runway through mid-2028 suggest a reduced short-term risk of default.

Next Steps

• Report topline data for 80 patients in the Phase 2 ASPEN-09-Breast trial in mid-2027.
• Report safety data from the dose-escalation phase of the Phase 1 ALX2004 trial in 2H 2026.
• Continue to advance the development of evorpacept and ALX2004.
• Host webcast to discuss Q1 2026 financial results and ESMO Breast data.

Key Dates

Recommendation

The company is presenting encouraging early-stage data and has a strengthened financial position, but key data readouts are still some time away (mid-2027 for ASPEN-09-Breast). The significant increase in share count also warrants caution. A 'hold' recommendation reflects the balance of promising developments against the inherent risks and timelines in clinical-stage biotechnology.

Keywords

ALX Oncology, evorpacept, CD47 inhibitor, HER2-positive breast cancer, oncology, clinical trials, biotechnology, financial results